NASDAQ$RNA

Atrium Therapeutics Inc · Q3 2020 earnings

Q3 2020 earnings ·

Headline financials

Total Revenue

$1.75M

No prior period
Capital Expenditures

-$855K

No prior period
Free Cash Flow

-$12.3M

No prior period
Net Income

-$11.4M

No prior period
Operating Income

-$11.5M

No prior period
Cash & Equivalents

$341M

No prior period
Total Assets

$346M

No prior period

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$1.75M

Q3 2020

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro